Drug Database
EQ

equine antithymocyte globulin (Thymogam)

✓ Approved

Bharat Serums and Vaccines Limited · Polyclonal Antibodies · Polyclonal Antibodies

What is equine antithymocyte globulin?

equine antithymocyte globulin is a polyclonal antibodies developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesThymogam
CompanyBharat Serums and Vaccines Limited
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

equine antithymocyte globulin is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAplastic anaemia✓ Approved
Immune system disordersSolid organ transplant rejection✓ Approved

Related Research Articles

PubMedJournal of human immunity2026-07-17

Implementing calculated globulin screening for immunodeficiencies: The benefits and challenges.

Jolles Stephen S, Poli Cecilia C, Rider Nicholas L NL, Negritu Gabriela G et al.

There is a need for pragmatic and cost-effective methodologies to facilitate earlier diagnosis of patients with primary and secondary immunodeficiencies, who often experience diagnostic delays that impact their quality of life, morbidity, and mortality. This review article will consider the utility of calculated globulin (CG) as a simple and unbiased screening tool for immunodeficiencies. We review literature indicating that CG can serve as an inexpensive and routinely performed proxy for immunoglobulin levels due to their established correlation. We also set out a workflow for the implementation of CG into clinical practice and discuss optimal approaches to embedding into laboratory reporting systems, and integration of AI approaches could expedite diagnoses. Finally, we discuss the challenges and pitfalls of CG screening, including the need for established CG cutoffs/action values across different patient age cohorts. Collaboration among biochemistry and immunology laboratories, clinicians, and patient organizations will be required to manage the logistics of effective broader implementation of CG screening into clinical practice.

PubMedEuropean journal of gastroenterology & hepatology2026-07-17

Development of a machine learning-based noninvasive diagnostic model for liver fibrosis in metabolic-associated steatotic liver disease.

Hui Yixin Y, Zeng Yuping Y, Zhang Mei M

To address the lack of simple tools for assessing fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), this study develops a machine learning-based diagnostic model to identify patients at high risk of significant fibrosis and advanced fibrosis. Data from biopsy-proven MASLD patients were randomly divided into training and validation sets. Variables were then selected, and models using Logistic, Support Vector Machine, and eXtreme Gradient Boosting (XGBoost) were compared with identify the optimal model. Finally, Shapley Additive Explanations-based interpretability analysis was applied to explain the best-performing model. The DeLong test was applied to compare the new model with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 index (FIB-4) models. The XGBoost models demonstrated robust accuracy. For the significant fibrosis outcome, the model incorporating age, total cholesterol, glycosylated hemoglobin (HbA1c), and albumin/globulin ratio achieved an area under the receiver operating characteristic curve (AUC) of 0.74 in the training set and 0.72 in the testing set. Regarding the advanced fibrosis outcome, the model including age, total cholesterol, HbA1c, platelets, white cell count, and albumin/globulin ratio yielded an AUC of 0.78 in the training set and 0.74 in the testing set. Decision curve analysis curves confirmed clinical utility, and performance surpassed APRI and FIB-4 (P < 0.05). This study developed a novel noninvasive diagnostic model for MASLD using simple and easily accessible variables, which demonstrates superior performance compared with traditional serological models.

PubMedAmerican journal of veterinary research2026-07-17

Mares with severe equine asthma exhibit a narrower trachea than geldings in a retrospective radiographic study of 189 horses.

Arnaiz Saura Patricia P, Masseau Isabelle I, Lavoie Jean-Pierre JP, Mainguy-Seers Sophie S

To evaluate potential relationships between sex, asthma severity, and tracheal diameter in adult horses through the use of thoracic radiography. This was a retrospective case-control study of horses that underwent thoracic radiography at the Université de Montréal from 2018 through 2024. Horses were classified as control, mild/moderate asthma, or severe asthma (SEA) according to the latest consensus statement on equine asthma. To account for radiographic magnification and body size, standardized ratios of tracheal diameter relative to the fifth thoracic vertebral body length and aortic diameter were calculated. The effects of disease status, sex, and their interaction were analyzed using a 2-way ANOVA and Tukey multiple-comparisons test, with results presented as mean [SD] and 95% confidence intervals (CI) of the difference for significant pairwise comparisons. 189 horses were included. The trachea-to-fifth thoracic vertebral body length ratio differed by disease status, with an interaction between sex and disease, as SEA mares had a lower ratio (0.7 [SD, 0.1]) than SEA geldings (0.8 [SD, 0.1]; 95% CI, 0.03 to 0.2), control mares (0.8 [SD, 0.1]; 95% CI, 0.05 to 0.3), and mild/moderate asthma mares (0.8 [SD, 0.1]; 95% CI, 0.03 to 0.2). The trachea-to-aorta ratio was influenced by disease status as it was lower in SEA horses than in controls. Absolute tracheal diameter was affected by disease status and sex, with an interaction between both factors, with SEA mares exhibiting the narrowest trachea. Tracheal diameter is influenced by both sex and asthma status in horses. Whether this sex-related difference in tracheal diameter influences lung mechanics and exercise capacity remains to be investigated.

PubMedJournal of applied toxicology : JAT2026-07-17

Melatonin-Zinc MOFs Antimycotic, Molecular, and Antioxidant Protective Effects of Hepatic, Renal, and Testicular Dysfunctions Induced by Aflatoxin B1 in Rats.

Aly Mohamed S MS, Soliman Mona M H MMH, Balabel Esraa A EA, Abdelhameed Reda M RM et al.

Aflatoxin B1 causes renal, hepatic, and reproductive disorders. To investigate the protective effects of melatonin-zinc metal-organic frameworks (Mt-Zn-MOFs) nanoparticles against renal, hepatic, and reproductive toxicity induced by aflatoxins B1, male Sprague-Dawley rats (n = 40) were equally divided into control, Mt-Zn-MOFs, aflatoxins, and Mt-Zn-MOFs + aflatoxins groups. Blood and tissue samples were collected from the livers, kidneys, and testicles. Luteinizing hormone (LH), testosterone, estradiol (E2), interleukin-β (IL-β), transforming growth factor-β (TGF-β), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), total antioxidants (TAC), nitric oxide (NO), AST, ALT, and creatinine were measured. Hepatic DNA fragmentation and the expression of CRAT, CYP39A1, and JunB genes were determined. Mt-Zn-MOFs have more antimycotic effects against A. flavus than A. parasiticus, with MIC and MFC of 3.125 and 6.25 mg/mL for A. flavus and 12.5 and 25 mg/mL for A. parasiticus, and 6.25 mg/mL inhibited A. flavus and A. parasiticus sporulation. Mt-Zn-MOFs rats had high (p < 0.001) testosterone, LH, E2, glucose, but low (p < 0.01) SOD, total proteins, albumin, globulin, AST, and ALT, compared to controls. Mt-Zn-MOFs-aflatoxin group had lower (p < 0.01) LH, SOD, GPx, total proteins, globulin, glucose, TGF-β (p < 0.022), DNA fragmentation, and the expressions of JunB, CYP39A1, and CRAT, but high (p < 0.01) NO, CAT, and total cholesterol than aflatoxin-treated rats. Mt-Zn-MOFs protected the liver, kidney, and spermatogenesis to a large extent. Mt-Zn-MOFs maintained normal testicular, hepatic, and renal histopathology in the aflatoxin treatment. Regardless, aflatoxin caused severe renal toxicity, Mt-Zn-MOFs reversed the effects of toxins and restored their normality, and are recommended to treat aflatoxicosis and mycotic infections.

PubMedEFSA journal. European Food Safety Authority2026-07-17

Evaluation of confirmatory data following the Article 12 MRL review for quinmerac.

European Food Safety Authority (EFSA), Bellisai Giulia G, Bernasconi Giovanni G, Castellan Irene I et al.

The applicant BASF SE submitted a request to the competent national authority in Estonia to evaluate the confirmatory data for quinmerac, which had been identified as unavailable in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005. To address the data gap, new residue trials complaint with an adjusted, less critical Good Agricultural Practice (GAP) in sugar beet tops were submitted. The results from these trials are also relevant for extrapolation to fodder beet tops and were taken into account to revise the livestock dietary burden calculations. The data gap was considered satisfactorily addressed. The information provided allow confirming the tentative MRLs for liver, kidney and edible offal of ruminant and equine commodities at the current levels. The previously performed consumer risk assessment for quinmerac remains valid.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about equine antithymocyte globulin